<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04419363</url>
  </required_header>
  <id_info>
    <org_study_id>20200528104746</org_study_id>
    <nct_id>NCT04419363</nct_id>
  </id_info>
  <brief_title>Burosumab in Children and Adolescents With X-linked Hypophosphatemia</brief_title>
  <official_title>12-months of Treatment With Burosumab in Children and Adolescents With X-linked Hypophosphatemia: a Prospective Longitudinal Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bicetre Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bicetre Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective longitudinal cohort study we studied the efficacy and safety of burosumab
      in real-clinical practice for &lt;13- and &gt;13-years old children affected with X-linked
      hypophosphatemia.

      57 children with XLH were switched from conventional treatment to burosumab. After 12 months
      we assessed the efficacy and safety of treatment with burosumab on the whole cohort and
      separately on the cohort of &gt;13-years old adolescents.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2018</start_date>
  <completion_date type="Anticipated">September 16, 2022</completion_date>
  <primary_completion_date type="Actual">March 20, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiological changes in rachitic lesions evaluated with knee MRI</measure>
    <time_frame>12 months</time_frame>
    <description>maximum width of the physis and transverse extent of widening</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum phosphate</measure>
    <time_frame>12 months</time_frame>
    <description>mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal phosphate reabsorption</measure>
    <time_frame>12 months</time_frame>
    <description>mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alkaline phosphatase</measure>
    <time_frame>12 months</time_frame>
    <description>U/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1,25(OH)vitaminD</measure>
    <time_frame>12 months</time_frame>
    <description>pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>parathyroid hormone</measure>
    <time_frame>12 months</time_frame>
    <description>ng/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>height</measure>
    <time_frame>12 months</time_frame>
    <description>standard deviation score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional capacity</measure>
    <time_frame>12 months</time_frame>
    <description>6-minute walk test, standard deviation score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of dental abcesses</measure>
    <time_frame>12 months</time_frame>
    <description>dental examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of hearing problems</measure>
    <time_frame>12 months</time_frame>
    <description>ORL examination, audiogramm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of neurological problems (craniosynostosis, Chiari I malformation)</measure>
    <time_frame>12 months</time_frame>
    <description>neurosurgical examination and brain MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of nephrocalcinosis</measure>
    <time_frame>12 months</time_frame>
    <description>renal ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of hyperparathyroidism</measure>
    <time_frame>12 months</time_frame>
    <description>blood levels of parathyroid hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of any side effects</measure>
    <time_frame>12 months</time_frame>
    <description>registration of any side effects during the treatment by telephone call</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Rare Diseases</condition>
  <condition>X-linked Hypophosphatemia</condition>
  <arm_group>
    <arm_group_label>The whole cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children affected with X-linked hypophosphatemia of average age of 9.8 years were switch from conventional therapy to burosumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Burosumab Injection</intervention_name>
    <description>Children affected with X-linked hypophosphatemia were switched from conventional therapy to burosumab</description>
    <arm_group_label>The whole cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  insufficient response or refractory to conventional therapy;

          -  complications of conventional therapy: hypercalciuria and/or nephrocalcinosis, and/or
             persistent secondary hyperparathyroidism;

          -  need for rapid restoration of phosphate metabolism, e.g., late diagnosis (aged &gt;8
             years) and/or preparation for planned orthopaedic surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Bicetre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volha Zhukouskaya, MD, PhD</last_name>
      <phone>+33766681018</phone>
      <email>vzhukuskaya@genethon.fr</email>
    </contact>
    <investigator>
      <last_name>Agnès Linglart, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bicetre Hospital</investigator_affiliation>
    <investigator_full_name>Volha Zhukouskaya</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>X-linked hypophosphataemia</keyword>
  <keyword>fibroblast growth factor 23</keyword>
  <keyword>burosumab</keyword>
  <keyword>hyperparathyroidism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
    <mesh_term>Hypophosphatemia</mesh_term>
    <mesh_term>Rare Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

